New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
08:34 EDTCVMCEL-SCI reports 93% sequential enrollment increase in head and neck cancer trial
CEL-SCI announced that during the month of June the company enrolled 19 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine. A total of 54 patients were enrolled over the past three months, with 21 enrolled in April, 14 in May, and 19 in June. This marks a 93% increase over the prior three month period when a total of 28 patients were enrolled. So far, a total of 218 patients have been enrolled in the study. The study is expected to complete enrollment of 880 patients by the end of 2015. “As a result of active patient recruitment ongoing in an increasing number of clinical centers around the world, we are seeing the kind of acceleration we expect in patient enrollment numbers. With the United Kingdom having recently cleared our study, we are well past the halfway mark for country approvals. We are looking forward to receiving approvals from multiple additional countries later this year before being fully approved in all participating countries,” stated CEL-SCI CEO Geert Kersten.
News For CVM From The Last 14 Days
Check below for free stories on CVM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
08:11 EDTCVMCEL-SCI cleared to begin patient enrollment
Subscribe for More Information
July 22, 2014
08:32 EDTCVMCEL-SCI receives clearance to expand Multikine Phase III trial to Turkey
Subscribe for More Information
July 17, 2014
08:45 EDTCVMCEL-SCI expands Phase III head and neck cancer trial into Sri Lanka
CEL-SCI announced that Sri Lanka’s Ministry of Health has cleared the company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine in Sri Lanka. This follows similar clearance to conduct the Phase III study in the UK and Austria during the past weeks. Further expansion of the trial is underway with a goal to have a total of 880 patients enrolled through about 100 clinical centers in 20 countries by the end of 2015. The trial, which already has over 220 patients enrolled, is assessing the company’s investigational immunotherapeutic agent Multikine as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI's clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.
July 15, 2014
08:02 EDTCVMCEL-SCI receives $225K NIH research grant
CEL-SCI announced that it has been awarded a Phase I Small Business Innovation Research grant in the amount of $225K from the National Institute of Arthritis Muscoskeletal and Skin Diseases, which is part of the National Institutes of Health. The grant will fund the further development of CEL-SCI’s LEAPS technology as a potential treatment for rheumatoid arthritis. The NIH grant was awarded based on preliminary data by Tibor Glant’s team in collaboration with CEL-SCI showing that the administration of a proprietary peptide using CEL-SCI's LEAPS technology prevented the development, and lessened the severity, including inflammation, of experimental RA when it was administered after the disease was induced in the animals. This data was presented in May 2013 by Daniel Zimmerman, CEL-SCI’s senior vice president of research, cellular immunology, at the symposium on “Therapeutic Approaches to Autoimmunity” during the American Association of Immunologists 100th annual meeting in Honolulu, Hawaii.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use